Effective Neutralization of Daratumumab Effects on Pre-Transfusion Testing: a Method Modification

被引：1

作者：

Feldman, Anna ^{[1
]}

Duek, Adrian M. ^{[2
]}

Mandel-Benado, Mathilda ^{[1
,2
]}

Cohen, Liz A. ^{[1
]}

Feldman, Daniel R. ^{[3
]}

Leiba, Merav ^{[1
,2
]}

机构：

[1] Assuta Samson Univ Hosp, Blood Bank, Ashdod, Israel

[2] Assuta Samson Univ Hosp, Hematooncol Inst, Ashdod, Israel

[3] Ariel Univ, Dept Behav Sci, Ariel, Israel

来源：

CLINICAL LABORATORY | 2022年 / 68卷 / 09期

关键词：

immunohematology; patient blood management; RBC antigens and antibodies; INTERFERENCE;

D O I：

10.7754/Clin.Lab.2022.211243

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Background: The anti-CD38 antibody daratumumab is a common multiple myeloma treatment. As the erythrocyte's membrane expresses CD38, Daratumumab-treated samples show agglutination in serological pre-transfusion tests, hindering detection of erythrocyte alloantibodies. Dithiothreitol interferes with erythrocyte antigens, affecting investigation of unexpected antibodies. DARAEx (R), an anti-CD38 neutralizing agent, overcomes daratumumab-induced effects, without dithiothreitol's interferences. DARAEx (R) is applied only in Biorad columns. This study aimed to provide a DARAEx (R) protocol for application with the Grifols platform. Methods: We introduced a modified DARAEx (R) protocol (AssutaBB protocol) and performed antibody screenings on samples from nineteen daratumumab-treated patients. Results: The AssutaBB protocol provided antibody screen results for all patients, exactly as established in the default manufacturing protocol. Eleven patients presented natural negative antibody screens; eight presented positive K/E antibodies. Conclusions: AssutaBB allows the use of the more widespread Grifols platform in daratumumab-treated patients.

引用

页码：1977 / 1981

页数：5

共 50 条

[1] Effective Neutralization of Daratumumab Effects on Pre-Transfusion Testing: a Method Modification
Feldman, Anna
Duek, Adrian M.
Mandel-Benado, Mathilda
Cohen, Liz A.
Feldman, Daniel R.
Leiba, Merav
CLINICAL LABORATORY, 2022,
[2] Pre-transfusion testing
White, J.
ISBT SCIENCE SERIES, VOL 4, NO 1, STATE OF THE ART PRESENTATIONS, 2009, 4 (01): : 37 - 44
[3] DARATUMUMAB INTERFERES IN THE PRE-TRANSFUSION TESTS IN THE BLOOD BANK
Carreno Gomez-Tarragona, G.
Miras Calvo, F.
Montejano Ortega, L.
Cedena Romero, M. T.
Martinez Lopez, J.
HAEMATOLOGICA, 2015, 100 : 36 - 36
[4] Standard Lab Techniques Can Be Used to Overcome Daratumumab Interference with Pre-transfusion Testing
Lintel, N.
Brown, D.
Schafer, D. T.
Koepsell, S. A.
Shunkwiler, S. M.
TRANSFUSION, 2016, 56 : 138A - 139A
[5] INTERFERENCES IN PRE-TRANSFUSION TESTS IN PATIENTS TREATED WITH DARATUMUMAB
Pujol Balaguer, M. D. M.
Artaza, G.
Campoy, D.
Ene, G.
Jaramillo, A.
Olivera, P.
Pero, A.
Subira, M.
Velasquez, C.
Salinas, R.
HAEMATOLOGICA, 2017, 102 : 113 - 114
[6] Transfusion support and pre-transfusion testing in autoimmune haemolytic anaemia
Binsfeld, Marilene
Devey, Anais
Gothot, Andre
VOX SANGUINIS, 2024,
[7] A Pre-transfusion Testing Algorithm and Notification System for Patients on Daratumumab Can Reduce Turn-around Time
Vasovic, L. V.
Cai, C.
DeSimone, R. A.
Hsu, Y. S.
Goel, R.
Degtyaryova, D.
Parra, P.
Lo, D. T.
Rossi, A.
Cushing, M. M.
TRANSFUSION, 2016, 56 : 148A - 148A
[8] ALGORITHMS FOR SOLVING PROBLEMS OF PRE-TRANSFUSION IMMUNOHEMATOLOGICAL TESTING
Pashkova, I. A.
GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2019, 64 (02): : 222 - 233
[9] CURRENT CONCEPTS IN PRE-TRANSFUSION SEROLOGICAL COMPATIBILITY TESTING
Roxby, D.
VOX SANGUINIS, 2011, 101 : 1 - 2
[10] Validation of Daraex to Resolve Daratumumab-Induced Interferences in Pre-Transfusion Screen Tests
Tenorio, Maria
Jimenez, Gemma Moreno
Gutierrez, Valentin Garcia
Jimenez, Ana
Blanchard, Maria Jesus
Valles, Ana
Lopez, Sandra
Herrera, Pilar
Jimenez, Javier Lopez
Chinea, Anabelle
BLOOD, 2019, 134

← 1 2 3 4 5 →